rhPRL对骨髓移植小鼠结肠腺癌肺转移的实验性治疗及免疫机理初探

EFFECTS OF RECOMBINANT HUMAN PROLACTIN ON MURINE HEMAPOIESIS AND IMMUNE FUNCTION AND ITS UTILIZATION IN EXPERIMENTAL THERAPY OF MCA 38 BEARING MICE AFTER SYNGENEIC BONE MARROW TRANSPLANTATION

通过体内实验进一步观察荷瘤小鼠放疗加骨髓移植后并用ｒｈＰＲＬ的治疗效果。选用Ｃ５７ＢＬ／６纯系小鼠，静脉注入同基因结肠腺癌细胞（ＭＣＡ－３８），待定向形成大量肺转移结节（１０ｄ）时进行全身致死放疗并进行ＳＢＭＴ，同时进行ｒｈＰＲＬ治疗。在治疗开始的１０ｄ和２０ｄ分别处死部分动物观察肺癌结节、骨髓ＣＦＵ－Ｃ、脾脏Ｔ细胞丝裂原反应与ＮＫ活性，最终计算生存期。结果表明ｒｈＰＲＬ对荷瘤小鼠具明显的治疗效果，生存期明显延长（Ｐ＜０．０１），由ＨＢＳＳ组的４３．７ｄ延至６３．１ｄ。治疗后１０ｄ和２０ｄ的肺结节数比ＨＢＳＳ组明显减少（Ｐ＜０．０１），且同时造血系统（ＣＦＵ－Ｃ）和免疫功能（Ｔ细胞和ＮＫ细胞）回升较ＨＢＳＳ组明显（均为Ｐ＜０．０１）。提示ｒｈＰＲＬ在骨髓移植模型中可促进造血系统和免疫功能的重建，从而控制肿瘤的进展并延长生存期。

To study the in vivo effects of rhPRL on hemapoiesis and immune function,and its potential utilization in tumor immunotherapy combined with SBMT,the rhPRL(10 or 1 μg/day×10 days)was injected i.p. to lethal irradiated MCA 38 tumor bearing C57BL/6 mice after SBMT.The survival was significantly prolonged(P<0 01) from 43.7 days to 63.1 days compared with HBSS group.During the rhPRL treatment,the lung metastasis of tumor bearing mice was significantly decreased(P<0 01) from 21.7±2.2/lung to 8.9±1.3/lung at 10 d and 178.5±4.7/lung to 78.7±21.3/lung at 20 d.The marrow CFU C,splenic Con A mitogenesis and NK cytotoxicity were significantly increased respectively.The research indicated that the rhPRL may improve the reconstitution of murine hemapoiesis and immune function after SBMT and exert antitumor function in vivo.